| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Obesity | 29 | 2022 | 1076 | 4.710 |
Why?
|
| Heart Failure | 39 | 2022 | 1180 | 4.670 |
Why?
|
| Ventricular Function, Left | 28 | 2022 | 481 | 3.720 |
Why?
|
| Echocardiography | 27 | 2022 | 515 | 3.310 |
Why?
|
| Ventricular Dysfunction, Left | 13 | 2020 | 277 | 3.180 |
Why?
|
| Myocardial Infarction | 28 | 2020 | 807 | 3.070 |
Why?
|
| Hypertrophy, Left Ventricular | 13 | 2020 | 140 | 3.010 |
Why?
|
| Coronary Artery Disease | 21 | 2021 | 696 | 2.940 |
Why?
|
| Bariatric Surgery | 7 | 2021 | 90 | 2.750 |
Why?
|
| Ventricular Remodeling | 9 | 2020 | 318 | 2.470 |
Why?
|
| Obesity, Morbid | 8 | 2020 | 172 | 2.440 |
Why?
|
| Myocardial Contraction | 27 | 2017 | 383 | 2.210 |
Why?
|
| Computed Tomography Angiography | 17 | 2020 | 424 | 2.040 |
Why?
|
| Cardiovascular Diseases | 11 | 2022 | 940 | 2.010 |
Why?
|
| Coronary Angiography | 19 | 2021 | 866 | 1.950 |
Why?
|
| Adiposity | 3 | 2021 | 88 | 1.920 |
Why?
|
| Weight Loss | 13 | 2022 | 319 | 1.850 |
Why?
|
| Cardiac Catheterization | 9 | 2022 | 419 | 1.740 |
Why?
|
| Stroke Volume | 20 | 2022 | 586 | 1.700 |
Why?
|
| Myocardium | 33 | 2020 | 1204 | 1.620 |
Why?
|
| Heart Atria | 10 | 2022 | 206 | 1.600 |
Why?
|
| Heart Ventricles | 14 | 2017 | 738 | 1.600 |
Why?
|
| Calcium | 17 | 2015 | 929 | 1.490 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2022 | 99 | 1.380 |
Why?
|
| Exercise Tolerance | 6 | 2021 | 75 | 1.370 |
Why?
|
| Coronary Stenosis | 8 | 2019 | 246 | 1.350 |
Why?
|
| Metabolic Syndrome | 4 | 2021 | 191 | 1.350 |
Why?
|
| Humans | 129 | 2022 | 68618 | 1.340 |
Why?
|
| Heart | 20 | 2021 | 850 | 1.290 |
Why?
|
| Gastric Bypass | 8 | 2020 | 83 | 1.280 |
Why?
|
| Myocardial Perfusion Imaging | 4 | 2021 | 100 | 1.280 |
Why?
|
| Receptor, Insulin | 8 | 2012 | 71 | 1.260 |
Why?
|
| Body Mass Index | 11 | 2022 | 867 | 1.260 |
Why?
|
| Echocardiography, Stress | 6 | 2020 | 8 | 1.250 |
Why?
|
| Male | 120 | 2022 | 37321 | 1.200 |
Why?
|
| Tomography, X-Ray Computed | 17 | 2021 | 2324 | 1.170 |
Why?
|
| Echocardiography, Doppler | 9 | 2019 | 87 | 1.150 |
Why?
|
| Myocytes, Cardiac | 10 | 2010 | 442 | 1.080 |
Why?
|
| Sarcoplasmic Reticulum | 8 | 2006 | 40 | 1.060 |
Why?
|
| Female | 85 | 2022 | 38074 | 1.010 |
Why?
|
| Predictive Value of Tests | 18 | 2022 | 1465 | 1.010 |
Why?
|
| Middle Aged | 68 | 2021 | 21147 | 1.010 |
Why?
|
| Cardiomegaly | 11 | 2017 | 213 | 0.970 |
Why?
|
| Calcinosis | 4 | 2016 | 241 | 0.960 |
Why?
|
| Mitral Valve | 4 | 2018 | 166 | 0.930 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 232 | 0.920 |
Why?
|
| Exercise Test | 10 | 2020 | 242 | 0.910 |
Why?
|
| Coronary Vessels | 8 | 2018 | 313 | 0.910 |
Why?
|
| Aortic Valve Stenosis | 5 | 2017 | 177 | 0.880 |
Why?
|
| Blood Pressure | 16 | 2019 | 1451 | 0.880 |
Why?
|
| Hyperglycemia | 3 | 2014 | 158 | 0.870 |
Why?
|
| Risk Assessment | 12 | 2020 | 2007 | 0.850 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 87 | 0.850 |
Why?
|
| Aortic Valve Insufficiency | 1 | 2022 | 47 | 0.830 |
Why?
|
| Risk Factors | 21 | 2022 | 5731 | 0.790 |
Why?
|
| Angina Pectoris | 2 | 2019 | 61 | 0.790 |
Why?
|
| Transcatheter Aortic Valve Replacement | 3 | 2017 | 90 | 0.770 |
Why?
|
| Chest Pain | 7 | 2020 | 151 | 0.770 |
Why?
|
| Angina, Unstable | 3 | 2019 | 50 | 0.750 |
Why?
|
| Weight Reduction Programs | 1 | 2021 | 67 | 0.730 |
Why?
|
| Metabolic Diseases | 1 | 2020 | 37 | 0.710 |
Why?
|
| Mitochondria, Heart | 8 | 2015 | 53 | 0.700 |
Why?
|
| Pericardial Effusion | 1 | 2019 | 15 | 0.690 |
Why?
|
| Magnetic Resonance Imaging | 7 | 2021 | 2223 | 0.680 |
Why?
|
| Aged | 44 | 2022 | 14862 | 0.680 |
Why?
|
| Coronary Circulation | 3 | 2011 | 136 | 0.660 |
Why?
|
| Hemodynamics | 16 | 2021 | 705 | 0.650 |
Why?
|
| Adult | 42 | 2022 | 21403 | 0.640 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2019 | 237 | 0.620 |
Why?
|
| Heart Rate | 9 | 2010 | 568 | 0.620 |
Why?
|
| Exercise | 7 | 2021 | 658 | 0.620 |
Why?
|
| Captopril | 5 | 1999 | 22 | 0.620 |
Why?
|
| Animals | 70 | 2020 | 20881 | 0.610 |
Why?
|
| Prospective Studies | 17 | 2020 | 3705 | 0.600 |
Why?
|
| Diabetes Mellitus | 5 | 2020 | 694 | 0.590 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 6 | 1999 | 202 | 0.590 |
Why?
|
| Fractional Flow Reserve, Myocardial | 5 | 2019 | 137 | 0.590 |
Why?
|
| Diabetic Nephropathies | 2 | 2022 | 161 | 0.590 |
Why?
|
| Contrast Media | 9 | 2017 | 595 | 0.580 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2022 | 1085 | 0.560 |
Why?
|
| Adipocytes | 2 | 2017 | 88 | 0.560 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 4 | 2019 | 373 | 0.560 |
Why?
|
| Inflammation | 2 | 2013 | 1030 | 0.540 |
Why?
|
| Severity of Illness Index | 10 | 2022 | 1851 | 0.540 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2018 | 164 | 0.540 |
Why?
|
| Vascular Calcification | 4 | 2019 | 131 | 0.530 |
Why?
|
| Diastole | 7 | 2019 | 161 | 0.520 |
Why?
|
| Prognosis | 11 | 2019 | 2093 | 0.520 |
Why?
|
| Utah | 6 | 2020 | 27 | 0.510 |
Why?
|
| Dyspnea | 2 | 2019 | 87 | 0.500 |
Why?
|
| Abdominal Fat | 2 | 2012 | 8 | 0.490 |
Why?
|
| Venoms | 1 | 2014 | 6 | 0.480 |
Why?
|
| Hypoglycemic Agents | 4 | 2022 | 362 | 0.480 |
Why?
|
| Insulin Resistance | 4 | 2019 | 241 | 0.480 |
Why?
|
| Hospitalization | 2 | 2019 | 978 | 0.480 |
Why?
|
| Follow-Up Studies | 14 | 2020 | 3259 | 0.470 |
Why?
|
| Magnetic Resonance Imaging, Cine | 2 | 2011 | 83 | 0.470 |
Why?
|
| Treatment Outcome | 17 | 2020 | 7029 | 0.460 |
Why?
|
| Diabetes Mellitus, Type 1 | 3 | 2013 | 529 | 0.450 |
Why?
|
| Pacemaker, Artificial | 2 | 2015 | 157 | 0.440 |
Why?
|
| Purines | 2 | 2021 | 39 | 0.440 |
Why?
|
| Forecasting | 1 | 2014 | 277 | 0.440 |
Why?
|
| Heart Diseases | 3 | 2010 | 276 | 0.440 |
Why?
|
| Vasoconstriction | 1 | 2013 | 81 | 0.430 |
Why?
|
| Atrial Function, Left | 3 | 2020 | 10 | 0.430 |
Why?
|
| Transposition of Great Vessels | 2 | 2010 | 51 | 0.430 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 201 | 0.420 |
Why?
|
| Pericardium | 2 | 2020 | 97 | 0.420 |
Why?
|
| Sodium | 4 | 2002 | 161 | 0.420 |
Why?
|
| Arteries | 1 | 2013 | 108 | 0.420 |
Why?
|
| Atrial Fibrillation | 4 | 2021 | 249 | 0.410 |
Why?
|
| Diuretics | 1 | 2012 | 97 | 0.410 |
Why?
|
| Mice | 27 | 2020 | 8474 | 0.410 |
Why?
|
| Circadian Rhythm | 3 | 2008 | 218 | 0.410 |
Why?
|
| Diabetic Angiopathies | 1 | 2013 | 203 | 0.410 |
Why?
|
| Pyrazoles | 2 | 2021 | 190 | 0.400 |
Why?
|
| Heart Conduction System | 3 | 2010 | 119 | 0.400 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2011 | 4 | 0.400 |
Why?
|
| Hyperemia | 1 | 2011 | 14 | 0.400 |
Why?
|
| Heart Transplantation | 2 | 2011 | 328 | 0.390 |
Why?
|
| Calcium Signaling | 3 | 2000 | 97 | 0.390 |
Why?
|
| Sodium-Calcium Exchanger | 3 | 2002 | 69 | 0.390 |
Why?
|
| Hypertension | 11 | 2019 | 1535 | 0.390 |
Why?
|
| Atherosclerosis | 1 | 2013 | 204 | 0.380 |
Why?
|
| Peptides | 1 | 2014 | 455 | 0.380 |
Why?
|
| Signal Transduction | 15 | 2015 | 2689 | 0.380 |
Why?
|
| Longitudinal Studies | 4 | 2020 | 1054 | 0.380 |
Why?
|
| Adenosine | 1 | 2011 | 165 | 0.380 |
Why?
|
| Fatty Acids | 8 | 2020 | 222 | 0.370 |
Why?
|
| Vasodilator Agents | 1 | 2011 | 138 | 0.370 |
Why?
|
| Diiodothyronines | 2 | 2000 | 2 | 0.370 |
Why?
|
| Propionates | 2 | 2000 | 21 | 0.360 |
Why?
|
| Kidney | 4 | 2012 | 945 | 0.350 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2010 | 25 | 0.350 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 1536 | 0.350 |
Why?
|
| Machine Learning | 4 | 2019 | 170 | 0.350 |
Why?
|
| Insulin | 7 | 2015 | 619 | 0.340 |
Why?
|
| Mice, Knockout | 13 | 2017 | 1692 | 0.340 |
Why?
|
| Rabbits | 9 | 2006 | 509 | 0.340 |
Why?
|
| Retrospective Studies | 20 | 2021 | 7277 | 0.330 |
Why?
|
| Liver | 5 | 2021 | 1118 | 0.330 |
Why?
|
| Cardiomyopathies | 2 | 2007 | 167 | 0.330 |
Why?
|
| Cardiac Catheters | 2 | 2019 | 12 | 0.320 |
Why?
|
| Reproducibility of Results | 8 | 2019 | 2077 | 0.320 |
Why?
|
| Catheter Ablation | 2 | 2021 | 229 | 0.320 |
Why?
|
| Ventricular Function, Right | 3 | 2019 | 103 | 0.310 |
Why?
|
| Graft Rejection | 1 | 2011 | 458 | 0.310 |
Why?
|
| Radiographic Image Enhancement | 1 | 2009 | 208 | 0.310 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2008 | 117 | 0.310 |
Why?
|
| Time Factors | 13 | 2020 | 4655 | 0.310 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 323 | 0.300 |
Why?
|
| Sensitivity and Specificity | 7 | 2021 | 1753 | 0.290 |
Why?
|
| Body Weight | 4 | 2017 | 554 | 0.290 |
Why?
|
| Prostheses and Implants | 3 | 2020 | 159 | 0.290 |
Why?
|
| Cardiotonic Agents | 3 | 2005 | 71 | 0.290 |
Why?
|
| Integrin alpha5 | 1 | 2006 | 2 | 0.290 |
Why?
|
| Disease Models, Animal | 12 | 2017 | 2550 | 0.280 |
Why?
|
| Gap Junctions | 1 | 2006 | 29 | 0.280 |
Why?
|
| Rats | 24 | 2009 | 5300 | 0.280 |
Why?
|
| Gadolinium | 2 | 2017 | 88 | 0.270 |
Why?
|
| Diabetes Mellitus, Experimental | 4 | 2012 | 195 | 0.270 |
Why?
|
| Systole | 5 | 2011 | 149 | 0.270 |
Why?
|
| Lipid Metabolism | 3 | 2020 | 186 | 0.260 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2006 | 107 | 0.260 |
Why?
|
| Hypoxia | 1 | 2006 | 169 | 0.260 |
Why?
|
| Heart-Assist Devices | 3 | 2018 | 221 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2017 | 129 | 0.260 |
Why?
|
| Membrane Proteins | 3 | 2017 | 617 | 0.260 |
Why?
|
| Acute Coronary Syndrome | 2 | 2017 | 195 | 0.250 |
Why?
|
| Muscle Proteins | 3 | 2007 | 94 | 0.250 |
Why?
|
| Glucose Transporter Type 4 | 3 | 2017 | 34 | 0.240 |
Why?
|
| Diet, Mediterranean | 2 | 2022 | 12 | 0.240 |
Why?
|
| Atrial Pressure | 3 | 2021 | 9 | 0.240 |
Why?
|
| Papillary Muscles | 4 | 2006 | 30 | 0.230 |
Why?
|
| Risk Reduction Behavior | 2 | 2018 | 174 | 0.230 |
Why?
|
| Mice, Transgenic | 6 | 2013 | 1033 | 0.230 |
Why?
|
| Ion Transport | 2 | 2000 | 26 | 0.230 |
Why?
|
| Quality of Life | 4 | 2021 | 1515 | 0.220 |
Why?
|
| Quercetin | 3 | 2007 | 16 | 0.220 |
Why?
|
| Image Enhancement | 2 | 2017 | 143 | 0.220 |
Why?
|
| Ventricular Pressure | 2 | 2019 | 82 | 0.210 |
Why?
|
| Pulmonary Wedge Pressure | 4 | 2022 | 102 | 0.210 |
Why?
|
| In Vitro Techniques | 11 | 2012 | 765 | 0.210 |
Why?
|
| Sex Factors | 4 | 2019 | 1266 | 0.210 |
Why?
|
| Potassium | 1 | 2002 | 168 | 0.210 |
Why?
|
| Gene Expression Regulation | 5 | 2011 | 1293 | 0.210 |
Why?
|
| Diabetic Cardiomyopathies | 2 | 2020 | 17 | 0.200 |
Why?
|
| Aorta | 5 | 2017 | 316 | 0.200 |
Why?
|
| Cor Triatriatum | 1 | 2021 | 5 | 0.200 |
Why?
|
| Aged, 80 and over | 12 | 2020 | 4848 | 0.200 |
Why?
|
| Body Size | 1 | 2021 | 39 | 0.200 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2021 | 24 | 0.200 |
Why?
|
| Evaluation Studies as Topic | 3 | 2019 | 219 | 0.200 |
Why?
|
| Nutritional Sciences | 1 | 2021 | 21 | 0.200 |
Why?
|
| Dyslipidemias | 2 | 2019 | 98 | 0.190 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2021 | 40 | 0.190 |
Why?
|
| Arteriosclerosis | 2 | 2011 | 137 | 0.190 |
Why?
|
| Diet | 3 | 2021 | 514 | 0.190 |
Why?
|
| Carrier Proteins | 3 | 2009 | 597 | 0.190 |
Why?
|
| Overweight | 2 | 2019 | 186 | 0.190 |
Why?
|
| Subcutaneous Fat | 1 | 2020 | 5 | 0.190 |
Why?
|
| Intra-Abdominal Fat | 1 | 2020 | 11 | 0.190 |
Why?
|
| Aortic Valve | 3 | 2017 | 249 | 0.190 |
Why?
|
| Organ Size | 8 | 2016 | 242 | 0.190 |
Why?
|
| Fibrosis | 4 | 2010 | 371 | 0.180 |
Why?
|
| Hypotension | 1 | 2021 | 74 | 0.180 |
Why?
|
| Germany | 1 | 2020 | 67 | 0.180 |
Why?
|
| Isoproterenol | 4 | 2005 | 163 | 0.180 |
Why?
|
| Standard of Care | 1 | 2020 | 22 | 0.180 |
Why?
|
| Cohort Studies | 4 | 2020 | 2358 | 0.180 |
Why?
|
| Action Potentials | 4 | 2005 | 223 | 0.180 |
Why?
|
| Radiation Dosage | 3 | 2017 | 419 | 0.170 |
Why?
|
| Defibrillators, Implantable | 2 | 2015 | 329 | 0.170 |
Why?
|
| Vascular Stiffness | 1 | 2019 | 31 | 0.170 |
Why?
|
| Costs and Cost Analysis | 1 | 2020 | 193 | 0.170 |
Why?
|
| Electrocardiography | 6 | 2016 | 601 | 0.170 |
Why?
|
| Pulmonary Circulation | 1 | 2019 | 79 | 0.170 |
Why?
|
| Transducers, Pressure | 1 | 2019 | 14 | 0.170 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2020 | 100 | 0.170 |
Why?
|
| Waist-Hip Ratio | 2 | 2010 | 14 | 0.170 |
Why?
|
| Natriuretic Peptides | 1 | 2019 | 12 | 0.170 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2019 | 9 | 0.170 |
Why?
|
| Life Style | 1 | 2021 | 338 | 0.170 |
Why?
|
| Propranolol | 1 | 1999 | 103 | 0.170 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 43 | 0.160 |
Why?
|
| Oxidative Stress | 7 | 2015 | 718 | 0.160 |
Why?
|
| Drainage | 1 | 2019 | 133 | 0.160 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2019 | 75 | 0.160 |
Why?
|
| Disease Progression | 3 | 2011 | 1038 | 0.160 |
Why?
|
| Incidence | 2 | 2020 | 1603 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2006 | 2083 | 0.160 |
Why?
|
| Mortality | 1 | 2019 | 163 | 0.160 |
Why?
|
| Cachexia | 1 | 2019 | 54 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 931 | 0.160 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1999 | 189 | 0.160 |
Why?
|
| Pediatric Obesity | 1 | 2019 | 92 | 0.160 |
Why?
|
| Myocardial Ischemia | 1 | 2019 | 172 | 0.150 |
Why?
|
| Multivariate Analysis | 4 | 2019 | 1046 | 0.150 |
Why?
|
| Phenotype | 4 | 2017 | 947 | 0.150 |
Why?
|
| Heart Function Tests | 2 | 2016 | 33 | 0.150 |
Why?
|
| Health Status | 2 | 2012 | 429 | 0.150 |
Why?
|
| Oxygen Consumption | 5 | 2012 | 258 | 0.150 |
Why?
|
| Trans-Activators | 2 | 2011 | 237 | 0.150 |
Why?
|
| Primary Prevention | 1 | 2018 | 115 | 0.150 |
Why?
|
| Erythrocytes | 1 | 2018 | 137 | 0.150 |
Why?
|
| Cardiomegaly, Exercise-Induced | 1 | 2017 | 2 | 0.150 |
Why?
|
| Electric Stimulation | 4 | 2005 | 218 | 0.150 |
Why?
|
| Diet, High-Fat | 1 | 2018 | 81 | 0.150 |
Why?
|
| Physician's Role | 1 | 2018 | 116 | 0.150 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2011 | 141 | 0.150 |
Why?
|
| Cardiac Output, Low | 5 | 1996 | 52 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2010 | 710 | 0.150 |
Why?
|
| PPAR gamma | 2 | 2008 | 95 | 0.150 |
Why?
|
| Rats, Inbred Strains | 7 | 1992 | 532 | 0.150 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 792 | 0.150 |
Why?
|
| Pancreatic Neoplasms | 3 | 1995 | 332 | 0.150 |
Why?
|
| Cardiac Pacing, Artificial | 3 | 2005 | 174 | 0.150 |
Why?
|
| Case-Control Studies | 4 | 2020 | 1553 | 0.140 |
Why?
|
| Cardiac Output | 2 | 2020 | 133 | 0.140 |
Why?
|
| Tin | 1 | 2016 | 16 | 0.140 |
Why?
|
| Angina, Stable | 1 | 2016 | 13 | 0.140 |
Why?
|
| Nutrition Surveys | 1 | 2018 | 208 | 0.140 |
Why?
|
| Sinus of Valsalva | 1 | 1996 | 9 | 0.140 |
Why?
|
| Multidetector Computed Tomography | 1 | 2017 | 60 | 0.140 |
Why?
|
| Aortic Rupture | 1 | 1996 | 32 | 0.140 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2017 | 63 | 0.140 |
Why?
|
| Aortography | 1 | 2017 | 72 | 0.140 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 1996 | 25 | 0.140 |
Why?
|
| Sex Characteristics | 1 | 1999 | 295 | 0.140 |
Why?
|
| Wnt Signaling Pathway | 1 | 2017 | 57 | 0.140 |
Why?
|
| Gene Silencing | 1 | 2017 | 137 | 0.140 |
Why?
|
| Aorta, Abdominal | 1 | 2017 | 97 | 0.140 |
Why?
|
| Adaptation, Physiological | 3 | 2017 | 189 | 0.140 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 286 | 0.140 |
Why?
|
| ROC Curve | 4 | 2017 | 392 | 0.140 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2017 | 137 | 0.130 |
Why?
|
| Homeostasis | 3 | 2015 | 291 | 0.130 |
Why?
|
| Mitochondria | 3 | 2020 | 643 | 0.130 |
Why?
|
| Behavior Therapy | 1 | 2018 | 297 | 0.130 |
Why?
|
| Endothelium, Vascular | 1 | 2018 | 371 | 0.130 |
Why?
|
| Blotting, Western | 4 | 2013 | 954 | 0.130 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 2021 | 137 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2017 | 331 | 0.130 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2017 | 216 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2017 | 181 | 0.130 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2016 | 125 | 0.130 |
Why?
|
| Peripheral Arterial Disease | 1 | 2017 | 83 | 0.130 |
Why?
|
| Energy Metabolism | 3 | 2015 | 222 | 0.130 |
Why?
|
| Metalloporphyrins | 1 | 2015 | 25 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 8 | 2015 | 2791 | 0.130 |
Why?
|
| Outpatients | 1 | 2016 | 127 | 0.130 |
Why?
|
| Lower Extremity | 1 | 2017 | 153 | 0.130 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2019 | 450 | 0.130 |
Why?
|
| Survival Analysis | 6 | 2011 | 714 | 0.130 |
Why?
|
| Antioxidants | 2 | 2015 | 304 | 0.120 |
Why?
|
| Prosthesis-Related Infections | 1 | 2015 | 70 | 0.120 |
Why?
|
| Epoxy Compounds | 2 | 1991 | 20 | 0.120 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2013 | 118 | 0.120 |
Why?
|
| Primary Health Care | 1 | 2020 | 703 | 0.120 |
Why?
|
| Meglumine | 2 | 2011 | 16 | 0.120 |
Why?
|
| Oxidation-Reduction | 6 | 2013 | 567 | 0.120 |
Why?
|
| Pilot Projects | 2 | 2017 | 1342 | 0.120 |
Why?
|
| Decision Making | 1 | 2017 | 410 | 0.120 |
Why?
|
| Calcium Channels, L-Type | 2 | 2006 | 34 | 0.120 |
Why?
|
| Algorithms | 2 | 2010 | 1196 | 0.110 |
Why?
|
| Organometallic Compounds | 2 | 2011 | 95 | 0.110 |
Why?
|
| Biomarkers | 1 | 2019 | 1593 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 772 | 0.110 |
Why?
|
| United States | 6 | 2017 | 7367 | 0.110 |
Why?
|
| Protein Kinase C | 4 | 2009 | 270 | 0.110 |
Why?
|
| Survival Rate | 7 | 2019 | 1056 | 0.110 |
Why?
|
| Models, Cardiovascular | 3 | 2008 | 133 | 0.110 |
Why?
|
| Infusions, Intravenous | 3 | 2011 | 334 | 0.110 |
Why?
|
| Ultrasonography | 4 | 2021 | 453 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2017 | 1040 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 232 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1034 | 0.110 |
Why?
|
| Health Status Disparities | 1 | 2016 | 326 | 0.100 |
Why?
|
| Kidney Function Tests | 1 | 2012 | 114 | 0.100 |
Why?
|
| Regression Analysis | 2 | 2011 | 737 | 0.100 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 1992 | 153 | 0.100 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2013 | 116 | 0.100 |
Why?
|
| Embryonic Development | 1 | 2013 | 100 | 0.100 |
Why?
|
| Ion Channels | 2 | 2012 | 72 | 0.100 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 365 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 378 | 0.100 |
Why?
|
| Splanchnic Nerves | 2 | 2022 | 2 | 0.100 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2011 | 6 | 0.100 |
Why?
|
| Young Adult | 6 | 2020 | 5717 | 0.100 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 110 | 0.100 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 1996 | 300 | 0.100 |
Why?
|
| Drug Dosage Calculations | 1 | 2011 | 9 | 0.100 |
Why?
|
| Mitochondrial Proteins | 2 | 2012 | 113 | 0.100 |
Why?
|
| Mastectomy, Modified Radical | 1 | 1991 | 6 | 0.100 |
Why?
|
| Stress, Physiological | 1 | 2013 | 215 | 0.100 |
Why?
|
| PPAR alpha | 2 | 2009 | 31 | 0.100 |
Why?
|
| Constriction, Pathologic | 2 | 2017 | 236 | 0.100 |
Why?
|
| Blood Flow Velocity | 2 | 2017 | 172 | 0.100 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 215 | 0.100 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 242 | 0.100 |
Why?
|
| Mountaineering | 1 | 2010 | 2 | 0.090 |
Why?
|
| Mammaplasty | 1 | 1991 | 41 | 0.090 |
Why?
|
| Health Status Indicators | 1 | 2011 | 117 | 0.090 |
Why?
|
| omega-N-Methylarginine | 1 | 2010 | 14 | 0.090 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 1998 | 468 | 0.090 |
Why?
|
| Altitude | 1 | 2010 | 17 | 0.090 |
Why?
|
| Gene Expression | 3 | 2009 | 770 | 0.090 |
Why?
|
| Nitroprusside | 1 | 2010 | 42 | 0.090 |
Why?
|
| Certification | 1 | 2011 | 66 | 0.090 |
Why?
|
| Dietary Supplements | 2 | 2018 | 332 | 0.090 |
Why?
|
| Ventricular Fibrillation | 1 | 2011 | 85 | 0.090 |
Why?
|
| Acetylcholine | 1 | 2010 | 64 | 0.090 |
Why?
|
| RNA, Messenger | 5 | 2008 | 1664 | 0.090 |
Why?
|
| Feasibility Studies | 3 | 2021 | 652 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2011 | 178 | 0.090 |
Why?
|
| Research Design | 1 | 2015 | 729 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 3 | 2015 | 137 | 0.090 |
Why?
|
| Waist Circumference | 1 | 2010 | 32 | 0.090 |
Why?
|
| Electrodes, Implanted | 1 | 2010 | 98 | 0.090 |
Why?
|
| Physical Fitness | 1 | 2011 | 117 | 0.090 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2010 | 52 | 0.090 |
Why?
|
| Cardiology | 1 | 2011 | 140 | 0.090 |
Why?
|
| Endotoxemia | 1 | 2009 | 27 | 0.090 |
Why?
|
| Waiting Lists | 1 | 2010 | 104 | 0.090 |
Why?
|
| Oleic Acids | 1 | 2009 | 40 | 0.090 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2010 | 38 | 0.090 |
Why?
|
| Hypertension, Renal | 1 | 2009 | 29 | 0.090 |
Why?
|
| Biopsy | 1 | 2011 | 540 | 0.090 |
Why?
|
| Logistic Models | 4 | 2018 | 1420 | 0.090 |
Why?
|
| Thromboembolism | 1 | 2010 | 91 | 0.090 |
Why?
|
| Immunoglobulin Light Chains | 1 | 1989 | 19 | 0.080 |
Why?
|
| Tachycardia, Ventricular | 1 | 2011 | 153 | 0.080 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2006 | 40 | 0.080 |
Why?
|
| Electrodes | 1 | 2010 | 147 | 0.080 |
Why?
|
| Chi-Square Distribution | 3 | 2017 | 546 | 0.080 |
Why?
|
| Acyl-CoA Dehydrogenase, Long-Chain | 1 | 2009 | 1 | 0.080 |
Why?
|
| Acyl-CoA Dehydrogenase | 1 | 2009 | 8 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2011 | 214 | 0.080 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2009 | 23 | 0.080 |
Why?
|
| Bradykinin | 1 | 2010 | 157 | 0.080 |
Why?
|
| Intracellular Fluid | 2 | 1999 | 24 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1989 | 36 | 0.080 |
Why?
|
| Mitochondrial Diseases | 1 | 2009 | 24 | 0.080 |
Why?
|
| C-Reactive Protein | 1 | 2010 | 180 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 331 | 0.080 |
Why?
|
| Women's Health | 1 | 2010 | 148 | 0.080 |
Why?
|
| Statistics as Topic | 2 | 2005 | 219 | 0.080 |
Why?
|
| Societies, Medical | 1 | 2011 | 403 | 0.080 |
Why?
|
| Receptors, Antigen, B-Cell | 1 | 1989 | 89 | 0.080 |
Why?
|
| Ventricular Function | 3 | 2003 | 93 | 0.080 |
Why?
|
| Patient Selection | 2 | 2010 | 592 | 0.080 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2008 | 42 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 58 | 0.080 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 3 | 2017 | 51 | 0.080 |
Why?
|
| Genotype | 1 | 2010 | 786 | 0.080 |
Why?
|
| Rats, Inbred SHR | 4 | 2009 | 95 | 0.080 |
Why?
|
| Europe | 2 | 2019 | 196 | 0.080 |
Why?
|
| Tricuspid Valve | 1 | 2008 | 42 | 0.080 |
Why?
|
| Blood Volume | 3 | 1993 | 47 | 0.080 |
Why?
|
| Acute Pain | 2 | 2020 | 35 | 0.080 |
Why?
|
| Reference Values | 4 | 2011 | 579 | 0.080 |
Why?
|
| Prosthesis Implantation | 2 | 2019 | 83 | 0.080 |
Why?
|
| Inflammation Mediators | 1 | 2009 | 244 | 0.080 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 201 | 0.080 |
Why?
|
| Recurrence | 2 | 2021 | 948 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 234 | 0.080 |
Why?
|
| North America | 2 | 2019 | 112 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 1 | 2009 | 492 | 0.080 |
Why?
|
| Liver Diseases | 1 | 2009 | 193 | 0.070 |
Why?
|
| Adolescent | 6 | 2020 | 8912 | 0.070 |
Why?
|
| Physical Conditioning, Animal | 1 | 2007 | 34 | 0.070 |
Why?
|
| Adenocarcinoma | 3 | 1995 | 475 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2010 | 631 | 0.070 |
Why?
|
| Diabetes Complications | 2 | 2005 | 249 | 0.070 |
Why?
|
| Microscopy, Electron | 4 | 2008 | 351 | 0.070 |
Why?
|
| Glucose | 3 | 2020 | 307 | 0.070 |
Why?
|
| Calreticulin | 1 | 2006 | 3 | 0.070 |
Why?
|
| Thermogenesis | 1 | 2006 | 5 | 0.070 |
Why?
|
| Prevalence | 3 | 2019 | 1619 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2009 | 307 | 0.070 |
Why?
|
| Cell Membrane Permeability | 1 | 2006 | 59 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2007 | 223 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2003 | 30 | 0.070 |
Why?
|
| Clinical Competence | 1 | 2011 | 657 | 0.070 |
Why?
|
| Cell Communication | 1 | 2006 | 116 | 0.070 |
Why?
|
| Chagas Disease | 1 | 2006 | 8 | 0.070 |
Why?
|
| Lung Neoplasms | 4 | 1996 | 1173 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2006 | 1200 | 0.070 |
Why?
|
| Isometric Contraction | 2 | 1999 | 33 | 0.070 |
Why?
|
| Connexin 43 | 1 | 2006 | 62 | 0.070 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2006 | 26 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2006 | 95 | 0.070 |
Why?
|
| Body Surface Potential Mapping | 1 | 2005 | 10 | 0.070 |
Why?
|
| Observer Variation | 2 | 2017 | 330 | 0.070 |
Why?
|
| Postoperative Complications | 3 | 1995 | 1615 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 93 | 0.060 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2005 | 61 | 0.060 |
Why?
|
| Fluorouracil | 3 | 1998 | 130 | 0.060 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2005 | 21 | 0.060 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2006 | 56 | 0.060 |
Why?
|
| Integrins | 1 | 2005 | 115 | 0.060 |
Why?
|
| Capillaries | 1 | 2005 | 105 | 0.060 |
Why?
|
| DNA | 2 | 2007 | 597 | 0.060 |
Why?
|
| Emphysema | 1 | 2005 | 32 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2003 | 219 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 150 | 0.060 |
Why?
|
| Adenosine Triphosphate | 2 | 2009 | 314 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 147 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 507 | 0.060 |
Why?
|
| Biological Transport, Active | 2 | 2002 | 49 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2006 | 682 | 0.060 |
Why?
|
| Aging | 3 | 2011 | 911 | 0.060 |
Why?
|
| Philadelphia | 2 | 1995 | 18 | 0.060 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2006 | 142 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1999 | 629 | 0.060 |
Why?
|
| Physical Exertion | 2 | 2017 | 75 | 0.060 |
Why?
|
| Comorbidity | 2 | 2019 | 1426 | 0.060 |
Why?
|
| Rats, Inbred WKY | 4 | 2009 | 48 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 2 | 1999 | 561 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 689 | 0.050 |
Why?
|
| Muscle Cells | 1 | 2002 | 30 | 0.050 |
Why?
|
| Patch-Clamp Techniques | 2 | 2000 | 204 | 0.050 |
Why?
|
| Remission Induction | 3 | 2017 | 111 | 0.050 |
Why?
|
| Ventricular Myosins | 1 | 2002 | 7 | 0.050 |
Why?
|
| Flavins | 1 | 2022 | 5 | 0.050 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2022 | 17 | 0.050 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 1 | 2022 | 20 | 0.050 |
Why?
|
| Phentermine | 1 | 2022 | 17 | 0.050 |
Why?
|
| Aequorin | 2 | 1999 | 3 | 0.050 |
Why?
|
| Fasting | 1 | 2022 | 75 | 0.050 |
Why?
|
| Luciferases | 1 | 2022 | 105 | 0.050 |
Why?
|
| Food Analysis | 1 | 2021 | 10 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2003 | 291 | 0.050 |
Why?
|
| Indoles | 3 | 2011 | 146 | 0.050 |
Why?
|
| Hepatitis B Virus, Woodchuck | 1 | 2001 | 2 | 0.050 |
Why?
|
| Arabinofuranosyluracil | 1 | 2001 | 3 | 0.050 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 1999 | 618 | 0.050 |
Why?
|
| Stochastic Processes | 1 | 2000 | 27 | 0.050 |
Why?
|
| Membrane Potentials | 2 | 1998 | 200 | 0.050 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2020 | 10 | 0.050 |
Why?
|
| Ligation | 1 | 2000 | 83 | 0.050 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2000 | 92 | 0.050 |
Why?
|
| Uncoupling Protein 3 | 2 | 2012 | 13 | 0.050 |
Why?
|
| Disease-Free Survival | 4 | 2011 | 349 | 0.050 |
Why?
|
| DNA, Viral | 1 | 2001 | 114 | 0.050 |
Why?
|
| Vascular Resistance | 2 | 2010 | 179 | 0.050 |
Why?
|
| Cell Size | 1 | 2000 | 76 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2019 | 9 | 0.040 |
Why?
|
| Angiotensin II | 2 | 1998 | 220 | 0.040 |
Why?
|
| Intracellular Membranes | 3 | 1995 | 86 | 0.040 |
Why?
|
| Anastomosis, Surgical | 1 | 2019 | 104 | 0.040 |
Why?
|
| Epidemiologic Methods | 1 | 2019 | 83 | 0.040 |
Why?
|
| Asia | 1 | 2019 | 59 | 0.040 |
Why?
|
| Tomography, Spiral Computed | 1 | 2019 | 57 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 1999 | 25 | 0.040 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2012 | 65 | 0.040 |
Why?
|
| Sarcopenia | 1 | 2019 | 9 | 0.040 |
Why?
|
| Lymphokines | 1 | 1999 | 49 | 0.040 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2019 | 7 | 0.040 |
Why?
|
| Cells, Cultured | 4 | 2008 | 2673 | 0.040 |
Why?
|
| Dietary Proteins | 1 | 2019 | 51 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2001 | 205 | 0.040 |
Why?
|
| Micronutrients | 1 | 2019 | 31 | 0.040 |
Why?
|
| Hematocrit | 2 | 2009 | 70 | 0.040 |
Why?
|
| Malnutrition | 1 | 2019 | 28 | 0.040 |
Why?
|
| Anti-Obesity Agents | 1 | 2019 | 42 | 0.040 |
Why?
|
| Carboplatin | 2 | 1995 | 59 | 0.040 |
Why?
|
| Fabaceae | 1 | 2018 | 12 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2001 | 211 | 0.040 |
Why?
|
| Fosinopril | 2 | 1995 | 2 | 0.040 |
Why?
|
| Dairy Products | 1 | 2018 | 13 | 0.040 |
Why?
|
| Dietary Sugars | 1 | 2018 | 7 | 0.040 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 301 | 0.040 |
Why?
|
| Alcoholic Beverages | 1 | 2018 | 18 | 0.040 |
Why?
|
| Apoptosis | 1 | 2005 | 1641 | 0.040 |
Why?
|
| Biophysical Phenomena | 1 | 1998 | 25 | 0.040 |
Why?
|
| Nifedipine | 1 | 1998 | 40 | 0.040 |
Why?
|
| Biophysics | 1 | 1998 | 41 | 0.040 |
Why?
|
| Diabetes, Gestational | 1 | 2019 | 81 | 0.040 |
Why?
|
| Blood Sedimentation | 1 | 2018 | 16 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2020 | 382 | 0.040 |
Why?
|
| Combined Modality Therapy | 4 | 1996 | 951 | 0.040 |
Why?
|
| Peroxidase | 1 | 2018 | 40 | 0.040 |
Why?
|
| Paclitaxel | 2 | 1995 | 140 | 0.040 |
Why?
|
| Vasoconstrictor Agents | 1 | 1998 | 107 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 1 | 2017 | 30 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 521 | 0.040 |
Why?
|
| Mutation | 3 | 2011 | 1213 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 1998 | 138 | 0.040 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 2017 | 5 | 0.040 |
Why?
|
| 3-Hydroxyacyl CoA Dehydrogenases | 1 | 2017 | 5 | 0.040 |
Why?
|
| Reactive Oxygen Species | 2 | 2012 | 499 | 0.040 |
Why?
|
| Constriction | 1 | 2017 | 37 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 1999 | 504 | 0.040 |
Why?
|
| Rats, Wistar | 2 | 1995 | 371 | 0.040 |
Why?
|
| Pre-Eclampsia | 1 | 2019 | 202 | 0.040 |
Why?
|
| Protein Phosphatase 2 | 1 | 2017 | 67 | 0.040 |
Why?
|
| 3T3-L1 Cells | 1 | 2017 | 30 | 0.040 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2017 | 18 | 0.040 |
Why?
|
| Aspirin | 1 | 2018 | 295 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2017 | 57 | 0.040 |
Why?
|
| Australia | 1 | 2017 | 235 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 280 | 0.040 |
Why?
|
| Regional Blood Flow | 1 | 2017 | 168 | 0.030 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1996 | 40 | 0.030 |
Why?
|
| Triiodobenzoic Acids | 1 | 2016 | 28 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 212 | 0.030 |
Why?
|
| Suicide | 1 | 2017 | 116 | 0.030 |
Why?
|
| Pyrazines | 1 | 1996 | 46 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 1996 | 52 | 0.030 |
Why?
|
| Surveys and Questionnaires | 3 | 2011 | 2800 | 0.030 |
Why?
|
| Prosthesis Design | 1 | 2017 | 301 | 0.030 |
Why?
|
| Swine | 1 | 2018 | 672 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 2016 | 108 | 0.030 |
Why?
|
| Angiotensinogen | 2 | 1993 | 18 | 0.030 |
Why?
|
| Cone-Beam Computed Tomography | 1 | 2016 | 52 | 0.030 |
Why?
|
| Electric Conductivity | 1 | 1996 | 87 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 733 | 0.030 |
Why?
|
| Renin-Angiotensin System | 2 | 1993 | 79 | 0.030 |
Why?
|
| Preoperative Care | 2 | 1995 | 275 | 0.030 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1995 | 57 | 0.030 |
Why?
|
| Pancreatic Cyst | 1 | 1995 | 16 | 0.030 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1995 | 18 | 0.030 |
Why?
|
| Pathology, Clinical | 1 | 1995 | 16 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2015 | 33 | 0.030 |
Why?
|
| Canada | 1 | 2016 | 267 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2018 | 377 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 1999 | 848 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 1999 | 508 | 0.030 |
Why?
|
| Risk | 2 | 2012 | 563 | 0.030 |
Why?
|
| Carcinoma, Adenosquamous | 1 | 1995 | 2 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2011 | 753 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1995 | 249 | 0.030 |
Why?
|
| Necrosis | 1 | 1995 | 239 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2018 | 1738 | 0.030 |
Why?
|
| Device Removal | 1 | 2015 | 100 | 0.030 |
Why?
|
| Radiology | 1 | 1995 | 97 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2017 | 506 | 0.030 |
Why?
|
| Lipids | 2 | 2007 | 298 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2009 | 567 | 0.030 |
Why?
|
| Coronary Disease | 2 | 2007 | 358 | 0.030 |
Why?
|
| Duodenal Neoplasms | 1 | 1993 | 9 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 786 | 0.030 |
Why?
|
| Mitomycin | 1 | 1993 | 27 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 880 | 0.030 |
Why?
|
| Pregnancy | 1 | 2019 | 2334 | 0.030 |
Why?
|
| Etoposide | 1 | 1993 | 64 | 0.030 |
Why?
|
| Thorax | 1 | 1993 | 49 | 0.030 |
Why?
|
| Muscles | 1 | 1993 | 158 | 0.030 |
Why?
|
| Ubiquitination | 1 | 2013 | 85 | 0.030 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2013 | 99 | 0.030 |
Why?
|
| South Carolina | 1 | 2019 | 2752 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2015 | 622 | 0.030 |
Why?
|
| Cisplatin | 1 | 1993 | 192 | 0.030 |
Why?
|
| Organelle Size | 1 | 2012 | 1 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 1996 | 756 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2011 | 18 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2011 | 26 | 0.030 |
Why?
|
| Hydroxyproline | 1 | 1991 | 33 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2012 | 61 | 0.030 |
Why?
|
| Hexokinase | 1 | 2011 | 3 | 0.020 |
Why?
|
| Fourier Analysis | 1 | 1991 | 31 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 122 | 0.020 |
Why?
|
| Oxidative Phosphorylation | 1 | 2011 | 54 | 0.020 |
Why?
|
| Proteome | 1 | 2012 | 87 | 0.020 |
Why?
|
| Glutathione | 1 | 2013 | 343 | 0.020 |
Why?
|
| Pyrroles | 1 | 2011 | 83 | 0.020 |
Why?
|
| Radiotherapy | 1 | 1991 | 86 | 0.020 |
Why?
|
| Colorectal Neoplasms | 1 | 1996 | 561 | 0.020 |
Why?
|
| Nepal | 1 | 2010 | 12 | 0.020 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 195 | 0.020 |
Why?
|
| Anthropometry | 1 | 2010 | 64 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 1991 | 172 | 0.020 |
Why?
|
| Respiratory Function Tests | 1 | 2010 | 123 | 0.020 |
Why?
|
| Benzamides | 1 | 2011 | 156 | 0.020 |
Why?
|
| Receptor, Bradykinin B1 | 1 | 2010 | 25 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 274 | 0.020 |
Why?
|
| Piperazines | 1 | 2011 | 206 | 0.020 |
Why?
|
| Age Distribution | 1 | 2011 | 320 | 0.020 |
Why?
|
| Ribosomal Protein S6 | 1 | 2009 | 3 | 0.020 |
Why?
|
| Receptor, Bradykinin B2 | 1 | 2010 | 75 | 0.020 |
Why?
|
| Blood Urea Nitrogen | 1 | 2009 | 65 | 0.020 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2009 | 26 | 0.020 |
Why?
|
| Aspartate Aminotransferases | 1 | 2009 | 87 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 2009 | 99 | 0.020 |
Why?
|
| Heart Block | 1 | 1989 | 49 | 0.020 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 137 | 0.020 |
Why?
|
| Body Temperature | 1 | 2009 | 116 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2011 | 332 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 82 | 0.020 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2009 | 13 | 0.020 |
Why?
|
| Chronic Disease | 3 | 2005 | 1330 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2009 | 201 | 0.020 |
Why?
|
| Electron Transport Complex I | 1 | 2009 | 20 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 243 | 0.020 |
Why?
|
| Electron Transport Complex IV | 1 | 2009 | 33 | 0.020 |
Why?
|
| Chemokines | 1 | 2009 | 119 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 160 | 0.020 |
Why?
|
| ARNTL Transcription Factors | 1 | 2008 | 6 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2009 | 110 | 0.020 |
Why?
|
| Biological Clocks | 1 | 2008 | 6 | 0.020 |
Why?
|
| Darkness | 1 | 2008 | 27 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 1991 | 800 | 0.020 |
Why?
|
| Cell Enlargement | 1 | 2008 | 2 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2009 | 83 | 0.020 |
Why?
|
| Sirolimus | 1 | 2009 | 118 | 0.020 |
Why?
|
| Muscle, Skeletal | 2 | 2006 | 396 | 0.020 |
Why?
|
| Peptide Elongation Factor 2 | 1 | 2008 | 14 | 0.020 |
Why?
|
| Uncoupling Protein 2 | 1 | 2008 | 18 | 0.020 |
Why?
|
| Ribonucleotides | 1 | 2008 | 26 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2009 | 199 | 0.020 |
Why?
|
| Aminoimidazole Carboxamide | 1 | 2008 | 25 | 0.020 |
Why?
|
| Child | 1 | 2019 | 6405 | 0.020 |
Why?
|
| Swimming | 1 | 2008 | 38 | 0.020 |
Why?
|
| Collagen | 1 | 1991 | 636 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2008 | 48 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2014 | 711 | 0.020 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 77 | 0.020 |
Why?
|
| Natriuretic Agents | 1 | 2008 | 9 | 0.020 |
Why?
|
| Dogs | 1 | 1989 | 490 | 0.020 |
Why?
|
| Adipokines | 1 | 2008 | 20 | 0.020 |
Why?
|
| Eating | 1 | 2008 | 119 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 1989 | 489 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 333 | 0.020 |
Why?
|
| Telemetry | 1 | 2007 | 23 | 0.020 |
Why?
|
| Plasma Volume | 1 | 2007 | 5 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 1989 | 258 | 0.020 |
Why?
|
| Pennsylvania | 1 | 2007 | 46 | 0.020 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2008 | 101 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2009 | 455 | 0.020 |
Why?
|
| Perfusion | 1 | 2007 | 131 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2007 | 166 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 195 | 0.020 |
Why?
|
| Curriculum | 1 | 2011 | 575 | 0.020 |
Why?
|
| Health Surveys | 1 | 2009 | 489 | 0.020 |
Why?
|
| Mesenteric Arteries | 1 | 2007 | 29 | 0.020 |
Why?
|
| Acetates | 1 | 2007 | 74 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1989 | 329 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2007 | 260 | 0.020 |
Why?
|
| Diet, Atherogenic | 1 | 2006 | 6 | 0.020 |
Why?
|
| Electron Transport Chain Complex Proteins | 1 | 2006 | 7 | 0.020 |
Why?
|
| Adrenergic Agents | 1 | 2006 | 14 | 0.020 |
Why?
|
| Body Fat Distribution | 1 | 2006 | 8 | 0.020 |
Why?
|
| Adipose Tissue, White | 1 | 2006 | 7 | 0.020 |
Why?
|
| Adipose Tissue, Brown | 1 | 2006 | 8 | 0.020 |
Why?
|
| Proteomics | 1 | 2009 | 246 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2007 | 246 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 615 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2006 | 90 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2007 | 320 | 0.020 |
Why?
|
| Blotting, Northern | 2 | 1999 | 189 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2007 | 308 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 25 | 0.020 |
Why?
|
| Trypanosoma cruzi | 1 | 2006 | 7 | 0.020 |
Why?
|
| Antibodies, Protozoan | 1 | 2006 | 15 | 0.020 |
Why?
|
| Norepinephrine | 1 | 2006 | 276 | 0.020 |
Why?
|
| Serologic Tests | 1 | 2006 | 46 | 0.020 |
Why?
|
| Serine | 1 | 2006 | 99 | 0.020 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2005 | 12 | 0.020 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2006 | 54 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2005 | 49 | 0.020 |
Why?
|
| Mesocricetus | 1 | 2005 | 32 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2005 | 19 | 0.020 |
Why?
|
| Cytokines | 1 | 2009 | 866 | 0.020 |
Why?
|
| Protein Kinase C-epsilon | 1 | 2005 | 28 | 0.020 |
Why?
|
| Immunoglobulin M | 1 | 2006 | 172 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 175 | 0.020 |
Why?
|
| RNA | 1 | 2006 | 171 | 0.020 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 1995 | 74 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 1996 | 125 | 0.020 |
Why?
|
| Cricetinae | 1 | 2005 | 262 | 0.020 |
Why?
|
| Biological Transport | 1 | 2005 | 210 | 0.020 |
Why?
|
| Thrombocytopenia | 2 | 1995 | 122 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2006 | 317 | 0.010 |
Why?
|
| Stearates | 1 | 2003 | 1 | 0.010 |
Why?
|
| Polylysine | 1 | 2003 | 13 | 0.010 |
Why?
|
| Antihypertensive Agents | 1 | 2007 | 498 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 791 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2010 | 2279 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 481 | 0.010 |
Why?
|
| Genetic Vectors | 1 | 2003 | 312 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 258 | 0.010 |
Why?
|
| Proteins | 1 | 2006 | 474 | 0.010 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2002 | 18 | 0.010 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2002 | 54 | 0.010 |
Why?
|
| Glycolysis | 1 | 2002 | 79 | 0.010 |
Why?
|
| Polymers | 1 | 2003 | 244 | 0.010 |
Why?
|
| Lipoproteins, LDL | 1 | 2003 | 343 | 0.010 |
Why?
|
| Marmota | 1 | 2001 | 4 | 0.010 |
Why?
|
| DNA, Circular | 1 | 2001 | 5 | 0.010 |
Why?
|
| Lamivudine | 1 | 2001 | 24 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 223 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 1047 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 77 | 0.010 |
Why?
|
| Epithelium | 1 | 1999 | 172 | 0.010 |
Why?
|
| Neoplasm Transplantation | 1 | 1999 | 160 | 0.010 |
Why?
|
| Phosphonoacetic Acid | 1 | 1998 | 5 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2001 | 1083 | 0.010 |
Why?
|
| Receptors, Angiotensin | 1 | 1998 | 59 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1998 | 160 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1999 | 238 | 0.010 |
Why?
|
| Genes, p53 | 1 | 1998 | 41 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2001 | 1447 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1998 | 46 | 0.010 |
Why?
|
| Aspartic Acid | 1 | 1998 | 65 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 1999 | 306 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1998 | 216 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1999 | 369 | 0.010 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 1996 | 3 | 0.010 |
Why?
|
| Ryanodine | 1 | 1996 | 7 | 0.010 |
Why?
|
| Thapsigargin | 1 | 1996 | 18 | 0.010 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 1996 | 16 | 0.010 |
Why?
|
| Inactivation, Metabolic | 1 | 1996 | 28 | 0.010 |
Why?
|
| Thiones | 1 | 1996 | 16 | 0.010 |
Why?
|
| Chemoprevention | 1 | 1996 | 26 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1996 | 60 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1996 | 124 | 0.010 |
Why?
|
| Pulmonary Surgical Procedures | 1 | 1996 | 3 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1999 | 1174 | 0.010 |
Why?
|
| Thiophenes | 1 | 1996 | 76 | 0.010 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 1996 | 98 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 1996 | 124 | 0.010 |
Why?
|
| Phenylephrine | 1 | 1995 | 61 | 0.010 |
Why?
|
| Drug Therapy | 1 | 1996 | 71 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1995 | 15 | 0.010 |
Why?
|
| Colon | 1 | 1996 | 168 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 1998 | 446 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 1995 | 37 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1996 | 219 | 0.010 |
Why?
|
| Arthralgia | 1 | 1995 | 30 | 0.010 |
Why?
|
| Neutropenia | 1 | 1995 | 72 | 0.010 |
Why?
|
| Stroke | 1 | 2007 | 2163 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 1995 | 125 | 0.010 |
Why?
|
| Osmolar Concentration | 1 | 1994 | 134 | 0.010 |
Why?
|
| Anemia | 1 | 1995 | 104 | 0.010 |
Why?
|
| Fatigue | 1 | 1995 | 132 | 0.010 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1993 | 8 | 0.010 |
Why?
|
| Atrophy | 1 | 1993 | 112 | 0.010 |
Why?
|
| Renin | 1 | 1993 | 96 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 1994 | 532 | 0.010 |
Why?
|
| Enalapril | 1 | 1992 | 86 | 0.010 |
Why?
|